Related references
Note: Only part of the references are listed.Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu et al.
SCIENCE (2018)
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Athanassios Argiris et al.
FRONTIERS IN ONCOLOGY (2017)
Nivolumab (Nivo) vs investigator's choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.
Robert L. Ferris et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab: the value of PDL1 biomarker in head and neck cancer
Raffaele Addeo et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
Jean-Pascal H. Machiels et al.
LANCET ONCOLOGY (2015)
The best partner for radiotherapy after induction chemotherapy in a larynx preservation strategy
Giuseppina Della Vittoria Scarpati et al.
ORAL ONCOLOGY (2014)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Share Paper
